In line with our results, VEGF-A rs699947A polymorphism seems to be associated with longer progression-free survival and overall survival in patients with renal cell carcinoma treated with sunitinib [29], whilst Masago et al. showed a positive prognostic role of VEGF-A rs699947C polymorphism in patients with non-small cell lung cancer [36]. This evidence concerns the gene VEGFA and hereditary clear cell renal cell carcinoma.